glp 1 and cannabinoids GLP-1 medications get at the heart of addiction: study – WashU Medicine CB1 blockade reduces GLP-1-stimulated AC

When Genetic Predisposition Matters: GLP-1 Pathway Variants and Treatment Response Recent genomics research shows variants in the glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), and metabolic genes like FTO (rs9939609) and MC4R (rs17782313) correlate with differential weight loss and glucose control on incretin-based therapies

Emerging research suggests GLP-1 receptor agonists may reduce inflammatory markers such as C-reactive protein and pro-inflammatory cytokines, though dedicated clinical trials examining low-dose regimens specifically for inflammation are lacking

NAD+ / NMN Increases cellular energy, provides anti-aging benefits, and supports longevity

Approval may be on the horizon

Whether through social media, traditional news outlets, or word of mouth, discussions about GLP-1 therapy are everywhere

However, it will almost certainly require a stringent prior authorization process